Cargando…

Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer

OBJECTIVE: To evaluate the distribution of high frequency mutant genes and the expression of PDL1 in different types of lung cancer. METHODS: This retrospective analysis was conducted on 330 patients who were diagnosed with primary lung cancer and treated in our hospital from October 2018 to October...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Rui, Gao, Shan, He, Haiqi, Zhang, Jia, Zhang, Guangjian, Wen, Xiaopeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449634/ https://www.ncbi.nlm.nih.gov/pubmed/34548813 http://dx.doi.org/10.2147/IJGM.S316151

Ejemplares similares

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
por: Heriyanto, Didik Setyo, et al.
Publicado: (2022)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
por: Shen, Shanxiang, et al.
Publicado: (2012)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

An advanced non-small cell lung cancer patient with EGFR and KRAS mutations, and PD-L1 positive, benefited from immunotherapy: a case report
por: Yang, Ronghua, et al.
Publicado: (2022)

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
por: Li, S, et al.
Publicado: (2014)

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
por: Borràs, Emma, et al.
Publicado: (2011)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
por: Udo, Emiko, et al.
Publicado: (2017)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis
por: McCourt, Clare M., et al.
Publicado: (2013)

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
por: Ma, Wanlong, et al.
Publicado: (2017)

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients
por: LEWANDOWSKA, MARZENA ANNA, et al.
Publicado: (2013)

Identification of the intersegmental plane by arterial ligation method during thoracoscopic segmentectomy
por: He, Haiqi, et al.
Publicado: (2022)

Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions
por: Yi, Chenghao, et al.
Publicado: (2016)

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
por: Chen, Nan, et al.
Publicado: (2017)

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013)

Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations
por: Poole, Jason C., et al.
Publicado: (2019)

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
por: Lee, Hong Kyu, et al.
Publicado: (2020)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer
por: Li, Shuo, et al.
Publicado: (2021)

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature
por: Zeng, Ran, et al.
Publicado: (2021)

Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
por: Xu, Yan, et al.
Publicado: (2017)

KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population
por: Hao, Yi-Xin, et al.
Publicado: (2017)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qrl8fipltbrah2iil55atv0irp